NanoSiliCal Devices prototypes are designed, developed and validated, according to specific chemo-physical and biological properties. Since, in the next future, many patents will expire, pharmaceutical companies would direct their attention on nanotechnology for drug delivery of already available drugs, in order to provide new products (different from generic ones) with improved safety and efficacy features, thus extending well-known brands market even after patents expiry.

Research in the oncologic field will, in particular, provide a solution to the problem of toxicity of traditional chemotherapeutic agents, through the development of innovative tools and technologies that will contribute to new therapies or patient interventions. (eg. by the addition of a targeting function selective for cancer cells).

Since cancer shows a growing trend, due to the lifestyle as well as the progressively ageing population, drug delivery would represent an efficient therapeutic approach for about 12.5 million new yearly diagnosed cancer cases worldwide. To this, we can add the new market of personalized medicine and a growing demand for self-administration drugs, also resulting in reduction of time spent in health facilities.

Oncology drug delivery market is, therefore, expected to increase from 11.3 billion dollars in the 2012 to 30,9 dollars in 2017, with a CAGR of 22.2%, while new drugs’ development and formulation should increase from about $ 9.4 billion in 2012 to nearly $ 20.5 billion in 2017, with a CAGR of 16.9%.

In this scenario, MSNs devices seem to be the ideal candidates to become new pharmaceutical products for drug targeting, since they are absent on the market, easily synthesized, versatile, biocompatible and soluble in biological fluids